Bank Pictet & Cie (Asia) Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neogen
NEOG
|
+$2.24M |
| 2 |
McDonald's
MCD
|
+$1.38M |
| 3 |
Expeditors International
EXPD
|
+$1.13M |
| 4 |
ASML
ASML
|
+$1.09M |
| 5 |
Microsoft
MSFT
|
+$942K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Starbucks
SBUX
|
+$1.45M |
| 2 |
Ross Stores
ROST
|
+$784K |
| 3 |
Dow Inc
DOW
|
+$780K |
| 4 |
Meta Platforms (Facebook)
META
|
+$760K |
| 5 |
UnitedHealth
UNH
|
+$487K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 28.99% |
| 2 | Consumer Staples | 16.42% |
| 3 | Healthcare | 14.07% |
| 4 | Technology | 12.29% |
| 5 | Financials | 11.56% |
Similar funds
Bank Pictet & Cie (Asia)'s Q4 2022 Portfolio in Review
As of Q4 2022, Bank Pictet & Cie (Asia) held 90 positions worth $278M, up 9.8% from $253M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Bank Pictet & Cie (Asia) deployed $8.57M of net new capital in Q4 2022, opening 3 new positions and adding to 53 existing holdings. Its largest new stake was Neogen: 157,000 shares worth $2.39M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 29% of assets, down from 30% a quarter earlier, followed by Consumer Staples and Healthcare.
On the sell side, the largest reduction was Starbucks, an estimated $1.45M trimmed.
- Bank Pictet & Cie (Asia)'s largest Q4 2022 buy was Neogen: 157,000 shares worth $2.39M.
- Bank Pictet & Cie (Asia) added most to McDonald's in Q4 2022, an estimated $1.38M increase.
- Bank Pictet & Cie (Asia)'s biggest Q4 2022 reduction was Starbucks, cutting an estimated $1.45M.
- Bank Pictet & Cie (Asia) fully exited Ross Stores in Q4 2022, selling an estimated $784K.
- Bank Pictet & Cie (Asia)'s ten largest holdings make up 58% of its $278M portfolio in Q4 2022.
- Bank Pictet & Cie (Asia) opened 3 new positions and closed 3 in Q4 2022.
- Bank Pictet & Cie (Asia)'s portfolio value rose 9.8% quarter-over-quarter to $278M.
Based on Bank Pictet & Cie (Asia)'s 13F filing for Q4 2022, filed 17 Feb 2023.